Treatment(s) now being considered-Hormonal therapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Hormonal therapy Posts on Medivizor

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Posted by on Aug 14, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT) and the benefit of extending the duration of ADT in men with localized prostate cancer (PCa). The data showed that the addition of ADT to RT and extending the duration of ADT administered after RT significantly improved the survival...

Read More

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Posted by on Jul 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) and docetaxel (Taxotere) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that darolutamide in combination with ADT and docetaxel significantly improved the overall...

Read More

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Posted by on May 8, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of abiraterone acetate (Zytiga; AA) and enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that both medication improve outcomes compared to placebo and ENZ is more effective in improving survival without cancer...

Read More

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...

Read More

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Posted by on Jan 19, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...

Read More

Aromatase inhibitors versus tamoxifen following chemotherapy for perimenopausal women with breast cancer

Aromatase inhibitors versus tamoxifen following chemotherapy for perimenopausal women with breast cancer

Posted by on Jul 31, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to assess the use of aromatase inhibitors (AI) versus tamoxifen (Novaldex) for women before menopause with estrogen receptor-positive (ER+) breast cancer (BC). The authors found that AIs were associated with better outcomes than tamoxifen in these patients.  Some background About 80% of all BCs...

Read More

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by on Jul 17, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of darolutamide (Nubeqa) with apalutamide (Erleada) and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (CRPC). The data showed that darolutamide was safer and had similar effectiveness compared to apalutamide and enzalutamide. Some background...

Read More

Real-world outcomes of fulvestrant as first-line treatment of postmenopausal women with advanced breast cancer.

Real-world outcomes of fulvestrant as first-line treatment of postmenopausal women with advanced breast cancer.

Posted by on Apr 10, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness of fulvestrant (Faslodex) as a first-line treatment for postmenopausal women with estrogen receptor-positive (ER+) metastatic breast cancer (BC) in a real-world setting. The data showed that the outcomes of these patients in the real-world setting were similar to clinical trials...

Read More

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Posted by on Jan 17, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC).   This study concluded that this combination provided positive outcomes for...

Read More

Which is safer for the heart: tamoxifen or letrozole?

Which is safer for the heart: tamoxifen or letrozole?

Posted by on Nov 30, 2020 in Breast cancer | 0 comments

In a nutshell This study compared the safety of two hormonal medications used to treat breast cancer, tamoxifen (Nolvadex) and letrozole (Femara). This study found that tamoxifen was associated with an increased risk of blood clots, while letrozole was associated with an increased risk of angina and heart attacks. Some background Hormone-positive...

Read More

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Posted by on Oct 23, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2022 Medivizor